Sanofi us­es cre­ative cam­ou­flage in physi­cian-tar­get­ed cam­paign for po­ten­tial can­cer bio­mark­er

As Sanofi stud­ies a new kind of can­cer drug, it’s prep­ping physi­cians for its po­ten­tial bio­mark­er ex­pres­sion.

Sanofi’s tusami­ta­m­ab rav­tan­sine is an an­ti­body-drug con­ju­gate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER